Edition:
India

ContraFect Corp (CFRX.OQ)

CFRX.OQ on NASDAQ Stock Exchange Capital Market

0.97USD
8:25pm IST
Change (% chg)

$-0.03 (-3.00%)
Prev Close
$1.00
Open
$1.03
Day's High
$1.04
Day's Low
$0.97
Volume
4,200
Avg. Vol
22,458
52-wk High
$2.65
52-wk Low
$0.80

Latest Key Developments (Source: Significant Developments)

ContraFect announces Q3 loss per share $0.02
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - ContraFect Corp <22R.SG>:ContraFect announces third quarter 2017 financial results.Q3 loss per share $0.02.ContraFect Corp - ‍As of Sept 30, 2017, had cash, cash equivalents and marketable securities of $52.6 million compared to $35.2 million as of December 31, 2016​.  Full Article

ContraFect qtrly loss per share $0.35
Tuesday, 9 Aug 2016 

ContraFect Corp :Qtrly loss per share $0.35.  Full Article

ContraFect files for pricing term sheet related to common stock offering
Friday, 22 Jul 2016 

ContraFect Corp : Says public offering priced at $2.50 per share of common stock and accompanying warrant to purchase one share of common stock .Files for pricing term sheet related to its common stock offering of 14 million shares - SEC filing.  Full Article

ContraFect names Steven Gilman chief executive officer
Friday, 22 Jul 2016 

ContraFect Corp : Gilman will continue to serve as chairman of board of directors of company .ContraFect Corporation names Steven C. Gilman, PhD chief executive officer.  Full Article

Contrafect announces proposed offering of common stock
Friday, 22 Jul 2016 

Contrafect Corp : Says Piper Jaffray & Co. Is Acting As Sole Book-Running manager for offering .Contrafect corporation announces proposed public offering of common stock and warrants.  Full Article

Contrafect reports Q1 loss per share of $0.32
Tuesday, 10 May 2016 

Contrafect Corp : Contrafect announces first quarter 2016 results .Q1 loss per share $0.32.  Full Article

ContraFect Corp concludes phase 1 Study of CF-301
Tuesday, 15 Dec 2015 

ContraFect Corp:Announces the Phase 1, first-in-human study of CF-301 has concluded.Says DSMB observed no clinical adverse safety signals associated with CF-301 in the study.  Full Article

BRIEF-ContraFect announces Q3 loss per share $0.02

* ContraFect Corp - ‍As of Sept 30, 2017, had cash, cash equivalents and marketable securities of $52.6 million compared to $35.2 million as of December 31, 2016​ Source text for Eikon: Further company coverage: